{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:34:26Z","timestamp":1789590866451,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus Dresden an der Technischen Universit\u00e4t Dresden"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>For patients (pts) with relapsed or refractory multiple myeloma (RRMM) after previous autologous hematopoietic cell transplantation (AHCT), novel agents, cellular and immunotherapies are increasingly available. Options for second-line treatment mostly include triplet regimens based on proteasome inhibitors, immunomodulatory drugs and anti-CD38 monoclonal antibodies and since recently also CAR T cells. The importance of autologous salvage transplantation (retransplantation, Re-AHCT) has significantly decreased in recent years due to the availability of many new treatment options. Therefore, we performed a retrospective analysis of 171 pts cases with RRMM who received Re-AHCT between 2002 and 2021. With a median follow-up of 74.7 months, the 5-year rates of progression-free survival (PFS) and overall survival (OS) were 18% (median 20.6 months) and 57% (median 65.0 months), respectively, the 100-day mortality rate was 4%. Multivariate analysis identified R-ISS stage and duration of previous response (DoR) as independent prognostic factors for PFS and OS. While the revealed high-risk population (R-ISS stage II\/III, DoR\u2009\u2264\u200924 months) was associated with a significantly worse PFS (HR 2.728) and OS (HR 3.129), the low-risk group (R-ISS I, DoR\u2009&gt;\u200924 months) achieved a median PFS and OS of 45.0 months and 80.2 months, respectively. Therefore, Re-AHCT could remain an option in such prognostically favorable pts with RRMM even in the era of novel therapies especially when more potent treatment modalities are not available.<\/jats:p>","DOI":"10.1007\/s00277-025-06262-9","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T02:01:42Z","timestamp":1740535302000},"page":"1735-1745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Is there still a place for autologous salvage transplantation in relapsed\/refractory multiple myeloma in the era of novel therapies?"],"prefix":"10.1007","volume":"104","author":[{"given":"Simone","family":"Karp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolin","family":"Trautmann-Grill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Warncke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Zolnowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Pannach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Zinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kroschinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Morgner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"von Bonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Fricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4767-3275","authenticated-orcid":false,"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9985-6583","authenticated-orcid":false,"given":"Raphael","family":"Teipel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"issue":"3","key":"6262_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","volume":"4","author":"B Dhakal","year":"2018","unstructured":"Dhakal B, Szabo A, Chhabra S, Hamadani M, D\u2019Souza A, Usmani SZ et al (2018) Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol 4(3):343\u2013350. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4600","journal-title":"JAMA Oncol"},{"issue":"2","key":"6262_CR2","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.2013.099358","volume":"99","author":"M Engelhardt","year":"2014","unstructured":"Engelhardt M, Terpos E, Kleber M, Gay F, W\u00e4sch R, Morgan G et al (2014) European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 99(2):232\u2013242. https:\/\/doi.org\/10.3324\/haematol.2013.099358","journal-title":"Haematologica"},{"issue":"2","key":"6262_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3324\/haematol.2017.174573","volume":"103","author":"F Gay","year":"2018","unstructured":"Gay F, Engelhardt M, Terpos E, W\u00e4sch R, Giaccone L, Auner HW et al (2018) From transplant to novel cellular therapies in multiple myeloma: European Myeloma network guidelines and future perspectives. Haematologica 103(2):197\u2013211. https:\/\/doi.org\/10.3324\/haematol.2017.174573","journal-title":"Haematologica"},{"issue":"4","key":"6262_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/10428194.2016.1228926","volume":"58","author":"L Garderet","year":"2017","unstructured":"Garderet L, Cook G, Auner HW, Bruno B, Lokhorst H, Perez-Simon JA et al (2017) Treatment options for relapse after autograft in multiple myeloma \u2013 report from an EBMT educational meeting. Leuk Lymphoma 58(4):797\u2013808. https:\/\/doi.org\/10.1080\/10428194.2016.1228926","journal-title":"Leuk Lymphoma"},{"issue":"10245","key":"6262_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/s0140-6736(20)30734-0","volume":"396","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D et al (2020) Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 396(10245):186\u2013197. https:\/\/doi.org\/10.1016\/s0140-6736(20)30734-0","journal-title":"Lancet"},{"issue":"2","key":"6262_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/nejmoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A et al (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372(2):142\u2013152. https:\/\/doi.org\/10.1056\/nejmoa1411321","journal-title":"N Engl J Med"},{"issue":"8","key":"6262_CR7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/nejmoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M et al (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375(8):754\u2013766. https:\/\/doi.org\/10.1056\/nejmoa1606038","journal-title":"N Engl J Med"},{"issue":"14","key":"6262_CR8","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/nejmoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ et al (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375(14):1319\u20131331. https:\/\/doi.org\/10.1056\/nejmoa1607751","journal-title":"N Engl J Med"},{"issue":"17","key":"6262_CR9","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/nejmoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L et al (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621\u20131634. https:\/\/doi.org\/10.1056\/nejmoa1516282","journal-title":"N Engl J Med"},{"issue":"6","key":"6262_CR10","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/s41375-020-01021-3","volume":"35","author":"M Dimopoulos","year":"2021","unstructured":"Dimopoulos M, Weisel K, Moreau P, Anderson LD, White D, San-Miguel J et al (2021) Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia 35(6):1722\u20131731. https:\/\/doi.org\/10.1038\/s41375-020-01021-3","journal-title":"Leukemia"},{"issue":"4","key":"6262_CR11","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.bbmt.2019.11.018","volume":"26","author":"S Giralt","year":"2020","unstructured":"Giralt S, Costa L, Maloney D, Krishnan A, Fei M, Antin J et al (2020) Tandem autologous-autologous versus autologous-allogeneic hematopoietic stem cell transplant for patients with multiple myeloma: long-term follow-up results from the blood and marrow transplant clinical trials network 0102 Trial. Biol Blood Marrow Transpl 26(4):798\u2013804. https:\/\/doi.org\/10.1016\/j.bbmt.2019.11.018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10301","key":"6262_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/s0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A et al (2021) Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 398(10301):665\u2013674. https:\/\/doi.org\/10.1016\/s0140-6736(21)01338-6","journal-title":"Lancet"},{"issue":"24","key":"6262_CR13","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/nejmoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodr\u00edguez-Otero P et al (2022) Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 387(24):2232\u20132244. https:\/\/doi.org\/10.1056\/nejmoa2204591","journal-title":"N Engl J Med"},{"issue":"9","key":"6262_CR14","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R et al (2023) Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 29(9):2259\u20132267. https:\/\/doi.org\/10.1038\/s41591-023-02528-9","journal-title":"Nat Med"},{"issue":"8","key":"6262_CR15","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/nejmoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384(8):705\u2013716. https:\/\/doi.org\/10.1056\/nejmoa2024850","journal-title":"N Engl J Med"},{"issue":"23","key":"6262_CR16","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1002\/cncr.34987","volume":"129","author":"AK Nooka","year":"2023","unstructured":"Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N et al (2023) Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial. Cancer 129(23):3746\u20133760. https:\/\/doi.org\/10.1002\/cncr.34987","journal-title":"Cancer"},{"issue":"5","key":"6262_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/bmt.2008.334","volume":"43","author":"RL Olin","year":"2009","unstructured":"Olin RL, Vogl DT, Porter DL, Luger SM, Schuster SJ, Tsai DE et al (2009) Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transpl 43(5):417\u2013422. https:\/\/doi.org\/10.1038\/bmt.2008.334","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"6262_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.bbmt.2011.10.044","volume":"18","author":"VH Jimenez-Zepeda","year":"2012","unstructured":"Jimenez-Zepeda VH, Mikhael J, Winter A, Franke N, Masih-Khan E, Trudel S et al (2012) Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transpl 18(5):773\u2013779. https:\/\/doi.org\/10.1016\/j.bbmt.2011.10.044","journal-title":"Biol Blood Marrow Transpl"},{"issue":"13","key":"6262_CR19","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1002\/cncr.28104","volume":"119","author":"L Sellner","year":"2013","unstructured":"Sellner L, Heiss C, Benner A, Raab MS, Hillengass J, Hose D et al (2013) Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. Cancer 119(13):2438\u20132446. https:\/\/doi.org\/10.1002\/cncr.28104","journal-title":"Cancer"},{"issue":"5","key":"6262_CR20","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.bbmt.2013.01.004","volume":"19","author":"LC Michaelis","year":"2013","unstructured":"Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI et al (2013) Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transpl 19(5):760\u2013766. https:\/\/doi.org\/10.1016\/j.bbmt.2013.01.004","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"6262_CR21","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.bbmt.2014.11.677","volume":"21","author":"KK Singh Abbi","year":"2015","unstructured":"Singh Abbi KK, Zheng J, Devlin SM, Giralt S, Landau H (2015) Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma. Biol Blood Marrow Transpl 21(3):468\u2013472. https:\/\/doi.org\/10.1016\/j.bbmt.2014.11.677","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"6262_CR22","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/bmt.2015.39","volume":"50","author":"M Gr\u00f6vdal","year":"2015","unstructured":"Gr\u00f6vdal M, Nahi H, Gahrton G, Liwing J, Waage A, Abildgaard N et al (2015) Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. Bone Marrow Transpl 50(6):808\u2013812. https:\/\/doi.org\/10.1038\/bmt.2015.39","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"6262_CR23","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1016\/s2352-3026(16)30049-7","volume":"3","author":"G Cook","year":"2016","unstructured":"Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD et al (2016) The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF myeloma X relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol 3(7):e340\u2013e351. https:\/\/doi.org\/10.1016\/s2352-3026(16)30049-7","journal-title":"Lancet Haematol"},{"issue":"7","key":"6262_CR24","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.bbmt.2018.01.035","volume":"24","author":"L Garderet","year":"2018","unstructured":"Garderet L, Iacobelli S, Koster L, Goldschmidt H, Johansson JE, Bourhis JH et al (2018) Outcome of a salvage third autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transpl 24(7):1372\u20131378. https:\/\/doi.org\/10.1016\/j.bbmt.2018.01.035","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"6262_CR25","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41375-020-1005-8","volume":"35","author":"B Dhakal","year":"2021","unstructured":"Dhakal B, D\u2019Souza A, Kleman A, Chhabra S, Mohan M, Hari P (2021) Salvage second transplantation in relapsed multiple myeloma. Leukemia 35(4):1214\u20131217. https:\/\/doi.org\/10.1038\/s41375-020-1005-8","journal-title":"Leukemia"},{"issue":"4","key":"6262_CR26","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41375-020-0948-0","volume":"35","author":"H Goldschmidt","year":"2021","unstructured":"Goldschmidt H, Baertsch MA, Schlenzka J, Becker N, Habermehl C, Hielscher T et al (2021) Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide\/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia 35(4):1134\u20131144. https:\/\/doi.org\/10.1038\/s41375-020-0948-0","journal-title":"Leukemia"},{"issue":"4","key":"6262_CR27","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41409-022-01592-y","volume":"57","author":"J Drozd-Soko\u0142owska","year":"2022","unstructured":"Drozd-Soko\u0142owska J, Gras L, Zinger N, Snowden JA, Arat M, Basak G et al (2022) Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation\u2013study on behalf of CMWP of the EBMT. Bone Marrow Transpl 57(4):633\u2013640. https:\/\/doi.org\/10.1038\/s41409-022-01592-y","journal-title":"Bone Marrow Transpl"},{"issue":"Supplement 1","key":"6262_CR28","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1182\/blood-2023-178835","volume":"142","author":"MA Baertsch","year":"2023","unstructured":"Baertsch MA, Schlenzka J, Hielscher T, Raab MS, Merz M, Mai EK et al (2023) Salvage autologous transplant and lenalidomide maintenance versus continuous lenalidomide\/dexamethasone for relapsed multiple myeloma: long term follow up results of the randomized GMMG Phase III Multicenter Trial Relapse. Blood 142(Supplement 1):782. https:\/\/doi.org\/10.1182\/blood-2023-178835","journal-title":"Blood"},{"issue":"11","key":"6262_CR29","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/s41409-023-02048-7","volume":"58","author":"R Tilmont","year":"2023","unstructured":"Tilmont R, Yakoub-Agha I, Eikema DJ, Zinger N, Haenel M, Schaap N et al (2023) Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the chronic malignancies working party of the EBMT. Bone Marrow Transpl 58(11):1182\u20131188. https:\/\/doi.org\/10.1038\/s41409-023-02048-7","journal-title":"Bone Marrow Transpl"},{"key":"6262_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02208-3","author":"S Sauer","year":"2024","unstructured":"Sauer S, Engelhardt M, Trautmann-Grill K, Kimmich C, H\u00e4nel M, Schmidt-Hieber M et al (2024) Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed\/refractory multiple myeloma in Germany. Bone Marrow Transpl. https:\/\/doi.org\/10.1038\/s41409-024-02208-3","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"6262_CR31","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467\u20131473. https:\/\/doi.org\/10.1038\/sj.leu.2404284","journal-title":"Leukemia"},{"issue":"8","key":"6262_CR32","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"6262_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-02278-5","volume-title":"The EBMT Handbook: hematopoietic stem cell transplantation and cellular therapies","author":"E Carreras","year":"2019","unstructured":"Carreras E, Dufour C, Mohty M, Kr\u00f6ger N (2019) The EBMT Handbook: hematopoietic stem cell transplantation and cellular therapies. Springer International Publishing, Cham"},{"issue":"7","key":"6262_CR34","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","volume":"34","author":"NJ Bahlis","year":"2020","unstructured":"Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M et al (2020) Daratumumab plus Lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 34(7):1875\u20131884. https:\/\/doi.org\/10.1038\/s41375-020-0711-6","journal-title":"Leukemia"},{"issue":"6","key":"6262_CR35","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/s1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E et al (2021) Daratumumab plus Pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 22(6):801\u2013812. https:\/\/doi.org\/10.1016\/s1470-2045(21)00128-5","journal-title":"Lancet Oncol"},{"issue":"8","key":"6262_CR36","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/jco.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A et al (2018) Improvement in overall survival with Carfilzomib, Lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. JCO 36(8):728\u2013734. https:\/\/doi.org\/10.1200\/jco.2017.76.5032","journal-title":"JCO"},{"issue":"24","key":"6262_CR37","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1182\/blood-2017-06-791228","volume":"130","author":"H Avet-Loiseau","year":"2017","unstructured":"Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L et al (2017) Ixazomib significantly prolongs progression-free survival in high-risk relapsed\/refractory myeloma patients. Blood 130(24):2610\u20132618. https:\/\/doi.org\/10.1182\/blood-2017-06-791228","journal-title":"Blood"},{"issue":"22","key":"6262_CR38","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1200\/jco.21.00972","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M et al (2021) Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol 39(22):2430\u20132442. https:\/\/doi.org\/10.1200\/jco.21.00972","journal-title":"J Clin Oncol"},{"issue":"7","key":"6262_CR39","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/nejmoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I et al (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373(7):621\u2013631. https:\/\/doi.org\/10.1056\/nejmoa1505654","journal-title":"N Engl J Med"},{"issue":"9","key":"6262_CR40","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","volume":"10","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J et al (2020) Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J 10(9):91. https:\/\/doi.org\/10.1038\/s41408-020-00357-4","journal-title":"Blood Cancer J"},{"issue":"6","key":"6262_CR41","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/s1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F et al (2019) Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol 20(6):781\u2013794. https:\/\/doi.org\/10.1016\/s1470-2045(19)30152-4","journal-title":"Lancet Oncol"},{"issue":"8","key":"6262_CR42","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.clml.2019.09.623","volume":"20","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Sonneveld P, Hungria V, Nooka AK, Estell JA, Barreto W et al (2020) Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. Clin Lymphoma Myeloma Leuk 20(8):509\u2013518. https:\/\/doi.org\/10.1016\/j.clml.2019.09.623","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"6262_CR43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s1470-2045(21)00579-9","volume":"23","author":"SZ Usmani","year":"2022","unstructured":"Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D et al (2022) Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol 23(1):65\u201376. https:\/\/doi.org\/10.1016\/s1470-2045(21)00579-9","journal-title":"Lancet Oncol"},{"issue":"10292","key":"6262_CR44","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/s0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T et al (2021) Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 397(10292):2361\u20132371. https:\/\/doi.org\/10.1016\/s0140-6736(21)00592-4","journal-title":"Lancet"},{"issue":"1","key":"6262_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-023-00797-8","volume":"13","author":"T Martin","year":"2023","unstructured":"Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T et al (2023) Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized phase 3 study. Blood Cancer J 13(1):1\u20139. https:\/\/doi.org\/10.1038\/s41408-023-00797-8","journal-title":"Blood Cancer J"},{"issue":"10214","key":"6262_CR46","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/s0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I et al (2019) Isatuximab plus Pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 394(10214):2096\u20132107. https:\/\/doi.org\/10.1016\/s0140-6736(19)32556-5","journal-title":"Lancet"},{"issue":"11","key":"6262_CR47","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.bbmt.2011.04.005","volume":"17","author":"G Cook","year":"2011","unstructured":"Cook G, Liakopoulou E, Pearce R, Cavet J, Morgan GJ, Kirkland K et al (2011) Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. Biol Blood Marrow Transpl 17(11):1638\u20131645. https:\/\/doi.org\/10.1016\/j.bbmt.2011.04.005","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"6262_CR48","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G et al (2021) Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 32(3):309\u2013322. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014","journal-title":"Ann Oncol"},{"issue":"11","key":"6262_CR49","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/nejmoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf Be, Patel K, Cavo M, Nooka AK et al (2023) Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 388(11):1002\u20131014. https:\/\/doi.org\/10.1056\/nejmoa2213614","journal-title":"N Engl J Med"},{"issue":"11","key":"6262_CR50","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/jco.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A et al (2023) Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. JCO 41(11):2087\u20132097. https:\/\/doi.org\/10.1200\/jco.22.01365","journal-title":"JCO"},{"issue":"4","key":"6262_CR51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/nejmoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV et al (2023) Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med 389(4):335\u2013347. https:\/\/doi.org\/10.1056\/nejmoa2303379","journal-title":"N Engl J Med"},{"issue":"16suppl","key":"6262_CR52","doi-asserted-by":"publisher","first-page":"e20017","DOI":"10.1200\/JCO.2023.41.16_suppl.e20017","volume":"41","author":"SM Larson","year":"2023","unstructured":"Larson SM, Bahlis NJ, Maisel C, Karlin L, Varshavsky Yanovsky A, Leip E et al (2023) Efficacy and safety of elranatamab in patients with high-risk relapsed\/refractory multiple myeloma (RRMM): a subgroup analysis from MagnetisMM-3. JCO 41(16suppl):e20017. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e20017","journal-title":"JCO"},{"issue":"6","key":"6262_CR53","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/nejmoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A et al (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387(6):495\u2013505. https:\/\/doi.org\/10.1056\/nejmoa2203478","journal-title":"N Engl J Med"},{"issue":"6","key":"6262_CR54","doi-asserted-by":"publisher","first-page":"e220186","DOI":"10.57264\/cer-2022-0186","volume":"12","author":"A Krishnan","year":"2023","unstructured":"Krishnan A, Nooka AK, Chari A, Garfall AL, Martin TG, Nair S et al (2023) Teclistamab versus real-world physician\u2019s choice of therapy in triple-class exposed relapsed\/refractory multiple myeloma. J Comp Eff Res 12(6):e220186. https:\/\/doi.org\/10.57264\/cer-2022-0186","journal-title":"J Comp Eff Res"},{"issue":"5","key":"6262_CR55","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1007\/s12325-023-02480-7","volume":"40","author":"P Moreau","year":"2023","unstructured":"Moreau P, van de Donk NWCJ, Delforge M, Einsele H, De Stefano V, Perrot A et al (2023) Comparative efficacy of Teclistamab Versus current treatments in real-world clinical practice in the prospective LocoMMotion Study in patients with triple-class-exposed relapsed and\/or refractory multiple myeloma. Adv Ther 40(5):2412\u20132425","journal-title":"Adv Ther"},{"issue":"2","key":"6262_CR56","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"C Riedhammer","year":"2024","unstructured":"Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A et al (2024) Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia 38(2):365\u2013371. https:\/\/doi.org\/10.1038\/s41375-024-02154-5","journal-title":"Leukemia"},{"issue":"1","key":"6262_CR57","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","volume":"14","author":"M Mohan","year":"2024","unstructured":"Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V et al (2024) Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J 14(1):35. https:\/\/doi.org\/10.1038\/s41408-024-01003-z","journal-title":"Blood Cancer J"},{"issue":"3","key":"6262_CR58","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jtct.2023.12.016","volume":"30","author":"D Dima","year":"2024","unstructured":"Dima D, Davis JA, Ahmed N, Jia X, Sannareddy A, Shaikh H et al (2024) Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience. Transpl Cell Ther 30(3):308.e1-308.e13 https:\/\/doi.org\/10.1016\/j.jtct.2023.12.016","journal-title":"Transpl Cell Ther"},{"issue":"16suppl","key":"6262_CR59","doi-asserted-by":"publisher","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","volume":"41","author":"CD Schinke","year":"2023","unstructured":"Schinke CD, Touzeau C, Minnema MC, van de Donk NWCJ, Rodr\u00edguez-Otero P, Mateos MV et al (2023) Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM). JCO 41(16suppl):8036\u20138036. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8036","journal-title":"JCO"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06262-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06262-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06262-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:10:59Z","timestamp":1745575859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06262-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6262"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06262-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"7 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the regional ethics committees of the State Chamber of Physicians of Saxony (EK-BR-40\/23\u2009\u2212\u20091).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patient consent was waived in accordance with the ethical approval due to retrospective design of the analysis and anonymization.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"K. Trautmann-Grill has received consultation fees and\/or honoraria from Sanofi, Takeda, Novartis, Amgen, GSK, Janssen; travel grants from Janssen, NovoNordisk, GSK, Sanofi and has participated in Data Safety Monitoring Board or advisory boards for Sanofi, Novartis, Amgen, GSK. M. H\u00e4nel has received consultations fees and\/or honoraria from Novartis, Amgen, GSK, Celgene, Sanofi-Aventis, Janssen, and Bristol-Myers Squibb. R. Herbst has received honoraria from Novartis, Bristol-Myers Squibb and Amgen. R. Teipel has participated in advisory boards or has received honoraria from Janssen, Bristol-Myers Squibb, Takeda, GSK, Gilead, Sanofi, Amgen, Stemline, Oncopeptides and Abbvie as well as research and travel grants from Janssen. All other authors declare no competing financial interests in relation to the work described. All authors declare that potential competing interests did not influence the content and results of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}